Welcome to Lab Test Consult

You can log in and post your comments

Share your knowledge and experience!

Member Login
Lost your password?

Quanterix Develops Microfluidic Consumable That Will Enable Next Generation Molecular Diagnostic Systems based on …

December 23, 2011
By


CAMBRIDGE, Mass. , Dec. 22, 2011 /PRNewswire/ — Quanterix Corporation, a company enabling a new generation of molecular diagnostic tests based on its revolutionary Single Molecule Array (SiMoA ™ ) technology, has reported a method for detecting individual proteins within microfabricated polymer arrays produced by Sony DADC.  Quanterix recently entered into a collaboration with Sony DADC for the development and manufacture of “smart consumables” based on an optical disc format.  This method was published online in Lab on a Chip.

“We have developed a device that enables the fluidic sealing and isolation of single molecules in arrays containing hundreds of thousands of miniaturized wells.  These consumables are manufactured using high precision and high volume manufacturing processes, and will be at the heart of the SiMoA instrument that we are currently developing.  By using arrays enclosed in microfluidic channels we are able to perform SiMoA in a fully automated fashion,” said David Duffy , Ph.D., Vice President of Research at Quanterix and corresponding author of the publication. “This represents a significant milestone towards our goal of developing an automated platform that enables single molecule sensitivity while offering significant advantages for the manufacture of high quality, low-cost consumables.  These devices will facilitate high throughput and sensitive detection of biomarkers, and address important applications in life science research and in vitro diagnostics.”

Martin Madaus , Ph.D., Quanterix Chairman and CEO added, “This achievement is an important step towards our goal to commercialize the SiMoA technology.  Working closely with our strategic partners, Quanterix plans to develop and manufacture a fully automated instrument for its SiMoA technology that will utilize these consumables to support a menu of diagnostic tests.  Quanterix expects to launch the life science instrument in 2013, followed by an IVD platform to be commercialized in 2014.”

About Quanterix

Quanterix Corporation is developing its proprietary Single Molecule Array (SiMoA™) technology for the in vitro diagnostics and life science research markets. The digital nature of SiMoA yields unprecedented assay performance, stemming from a 1,000-fold improvement in sensitivity compared with today’s analog only technology. SiMoA will enable researchers in life science to validate novel, low abundance biomolecules from a single droplet of blood, leading to greater insight into disease detection, diagnosis, therapy selection and disease monitoring. Automated systems based on SiMoA will provide diagnostic test information to healthcare practitioners faster, with greater reliability, unprecedented range and increased cost effectiveness.  Founded in 2007, the privately held Cambridge, Massachusetts -based company is backed by leading life science investors including ARCH Venture Partners, Bain Capital Ventures, and Flagship Ventures. For additional information, please visit www.quanterix.com.

 

Article source: http://finance.yahoo.com/news/quanterix-develops-microfluidic-consumable-enable-133000917.html

Share

Related posts:

  1. Accelr8 Announces Development Expansion for Blood-Based Diagnostic Tests
  2. DrFirst Joins the ATLAS iOn Interoperability Network to Enable Lab Test Ordering and Results Review Utilizing Rcopia
  3. Mt. Sinai to Launch Targeted Sequencing-Based Tests on PacBio RS for Autism, other Conditions
  4. Health Diagnostic Laboratory, Inc. Provides Largest Corporate Gift in Science Museum of Virginia’s History
  5. Accelr8 expands development plan for BACcel rapid diagnostic test
  6. New York State Clears Rosetta Genomics’ Array-based Cancer of Unknown Primary Test
  7. Lo’s Lab Readies T21 Test for Hong Kong, Looks to Additional Sequencing-based Prenatal Dx
  8. BGI Moves into the Clinical Space as Hong Kong Branch Aims to Build a Lab for Sequencing-Based Dx
  9. Breaking News: Unrivaled Diagnostic Testing Costs Savings for Physician Practices and Hospitals Nationwide
  10. Novartis gains European Commission approval for Rasitrio®, a Rasilez-based triple combination pill to treat high blood …

Tags:



New post

Posts

October 2017
M T W T F S S
« Aug    
 1
2345678
9101112131415
16171819202122
23242526272829
3031  

Posts

Recent comments

    Contact Sign In

    Email Marketing You Can Trust